10-Q: ALX Oncology Reports Q1 2026 Financials, Focuses on Evorpacept

ALX Oncology Holdings Inc. reported its first-quarter 2026 financial results, highlighting a significant reduction in operating expenses and a strong cash position, while continuing to advance its lead product candidate, evorpacept.

Summary

• ALX Oncology Holdings Inc. reported a net loss of $17.9 million for the three months ended March 31, 2026, a decrease from $30.8 million in the same period of 2025.
• Total operating expenses decreased by 40% to $19.0 million in Q1 2026 compared to $31.8 million in Q1 2025, primarily due to reduced research and development and general and administrative costs.
• The company ended the quarter with $169.1 million in cash, cash equivalents, and investments, and expects this to fund operations through the first half of 2028.
• Significant equity offerings in February 2026 provided substantial capital, with net proceeds of approximately $140.4 million.
• The company continues to advance its pipeline, with a focus on evorpacept, a CD47 blocker, and ALX2004, an EGFR-targeted antibody-drug conjugate.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as cautiously optimistic. While the company has reduced expenses and secured significant capital, it continues to operate at a substantial loss with no revenue, and its pipeline is still in early-stage development, presenting considerable risk.

Positives

• Significant reduction in operating expenses, with R&D expenses down 43% and G&A expenses down 32% year-over-year.
• Strong liquidity position with $169.1 million in cash, cash equivalents, and investments as of March 31, 2026.
• Successful completion of a registered offering in February 2026, raising approximately $140.4 million in net proceeds.
• Positive clinical data from the ASPEN-06 trial in gastric cancer, showing improved response rates and duration of response in patients with high CD47 expression when treated with evorpacept.
• Advancement of ALX2004 into Phase 1 clinical trials with no dose-limiting toxicities observed in the first two dose cohorts.

Negatives

• Continued net loss of $17.9 million in Q1 2026 and an accumulated deficit of $740.7 million as of March 31, 2026.
• The company has no products approved for sale and has not generated any revenue from product sales.
• The company anticipates continued significant expenses and operating losses for the foreseeable future.
• Previous topline data from ASPEN-03 and ASPEN-04 trials did not meet primary endpoints, leading to the discontinuation of evorpacept in combination with pembrolizumab for head and neck squamous cell carcinoma.
• The company received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, although it has since regained compliance.

Risks

• The company has incurred significant net losses since inception and expects to continue incurring significant net losses for the foreseeable future.
• Substantial additional capital will be required to finance operations, and such capital may not be available on acceptable terms.
• The company is substantially dependent on the success of its lead product candidate, evorpacept, which is in clinical development and has not completed a pivotal trial.
• Clinical trials are expensive, time-consuming, and may fail to demonstrate adequate safety, efficacy, or potency.
• The company relies on third-party manufacturers for clinical supplies, increasing the risk of supply disruptions.
• Macroeconomic conditions and global economic environment could adversely impact ongoing and planned clinical trials and preclinical research.

Future Outlook

The company believes its existing cash, cash equivalents, and investments, along with proceeds from recent equity offerings, will be sufficient to fund its operations through the first half of 2028. Management anticipates continued significant expenses and operating losses as it advances its product candidates through clinical development and seeks regulatory approvals.

Management Comments

• The company believes its existing capital resources will be sufficient to fund the projected operating requirements for at least the next twelve months.
• Management expects to incur additional losses in the future to conduct product candidate research and development and recognizes the need to raise additional capital to fully implement its business plan.
• The company is focused on evorpacept development with standard-of-care agents that provide a stimulatory signal to the innate immune system.
• The company anticipates that its general and administrative expenses will remain stable for the remainder of this year.

Industry Context

StockSavvy.ai notes that ALX Oncology is operating in the highly competitive immuno-oncology space, focusing on CD47 inhibition. The company's strategy of combining evorpacept with other targeted therapies aligns with industry trends aiming to enhance anti-tumor immune responses. The development of ALX2004 as an EGFR-targeted ADC addresses a significant area of unmet need in oncology.

Comparison to Industry Standards

• ALX Oncology's R&D expenses as a percentage of total operating expenses (approximately 72%) are typical for a clinical-stage biotechnology company heavily invested in pipeline development.
• The company's net loss per share of $(0.17) for the quarter is comparable to other early-stage biopharmaceutical companies that are pre-revenue.
• The significant increase in cash and investments from $46.6 million at the end of 2025 to $167.1 million by March 31, 2026, driven by equity financing, is a positive indicator of investor confidence in the company's development prospects, a common strategy for companies in this sector to fund lengthy clinical trials.

Management Changes

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Related Party Transactions

• The company had several related-party agreements with Tallac Therapeutics, Inc., with no material changes reported during the three months ended March 31, 2026.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings, but also potential upside if pipeline candidates are successful. The company's ability to maintain Nasdaq listing is a key concern.
• Employees: Continued focus on R&D and potential for growth if pipeline advances, but also risks associated with workforce reductions and the competitive hiring market.
• Creditors: The company has a term loan, and its ability to service debt depends on future financing and operational success.
• Suppliers/Partners: Continued reliance on third-party manufacturers and CROs, with potential risks if these relationships are disrupted.

Next Steps

• Continue advancing evorpacept through multiple clinical trials in various indications.
• Pursue regulatory approval of evorpacept in solid tumors and hematological malignancies.
• Advance ALX2004 through its first-in-human Phase 1 clinical trial.
• Continue preclinical and clinical development efforts for other pipeline candidates.
• Obtain and maintain patent, trade secret, and other intellectual property protection.
• Manufacture supplies for preclinical studies and clinical trials.
• Add operational, financial, and management information systems to support ongoing operations.

Key Dates

Recommendation

ALX Oncology presents a high-risk, high-reward profile typical of clinical-stage biotechs. While the company has made progress in reducing expenses and securing capital, its lack of revenue and reliance on the success of early-stage drug candidates means significant uncertainty remains. The positive clinical data for evorpacept in specific patient populations is encouraging, but the path to commercialization is long and fraught with regulatory and competitive risks. A 'hold' recommendation reflects the speculative nature of the investment, suitable for investors with a high risk tolerance who are monitoring pipeline developments closely.

Keywords

ALX Oncology, ALXO, 10-Q, Quarterly Report, Biotechnology, Oncology, Evorpacept, CD47 Blocker, ALX2004, EGFR ADC, Clinical Trials, Financial Results, SEC Filing